PK and Safety of Bocidelpar in Renal Impairment

Phase 1, open-label trial of bocidelpar in primary mitochondrial myopathy (PMM) and Duchenne muscular dystrophy (DMD) (4 arms), sponsored by Astellas Pharma. Primary endpoints: Area Under The Concentration-time Curve From Time of Dosing Extrapolated to Time Infinity up to 5 days, Area Under The Concentration-time Curve From The Time of Dosing to The Last Measurable Concentration up to 5 days and 2 more. Started Dec 2021; status: completed.